medigraphic.com
ISSN 1684-1824 (Electronic)

2021, Number 4

<< Back Next >>

Rev Méd Electrón 2021; 43 (4)

PO2/FiO2 index correlation with inflammatory and coagulation parameters in critically-ill patients with COVID-19 in Lombardy, 2020

García ÁPJ, Morejón RL, Grasso LF

Language: Spanish
References: 24
Page: 1-10
PDF size: 1180.97 Kb.


ABSTRACT

Introduction: the knowledge of disease physiopathology has revolutionized the traditional approach in the treatment of diseases caused by respiratory viruses. Currently, the markers of inflammatory answer are used to diagnose, stratify and predict in many cases the future behavior of COVID-19 patients.
Objective: to characterize the nature of the relationship between PO2/FiO2 (PAFI, Spanish acronym of PA= presión arterial [arterial pressure], FI=fracción inspirada [inspired fraction]) and coagulation and inflammatory parameters in seriously-ill patients with COVID-19, in the region of Lombardy, Italy.
Materials and methods: a retrospective, longitudinal, analytic study was carried out in 191 severe and critical patients who were admitted in Hospadale Maggiori di Crema, in the region of Lombardy, Italy, with the diagnosis of COVID-19, in the period April 1st-May 20, 2020.
Results: the evidenced correlations were the following: reactive C protein (-0.417) p=0; procalcitonin (PCT) (-0.152) p=0.018. D dimer (-0.112) p=0.061; Fibrinogen (-0.272) p=0.000; Plasma creatinine (-0.320) p=0.000; lymphocytes count (0,028) p=0,000; troponin (-0.028) p=0.142; and lactate (-0.191) p=0.288.
Conclusions: inflammatory markers play a capital role in the disease pathogenesis, and approaching this item of the medical anti-inflammatory treatment is mandatory. It is useful to keep a correct coagulation screening, using low molecular weight heparins, and also keeping an adequate hemodynamic support able to avoid cell dysoxia progressing to multiorgan failure.


REFERENCES

  1. Dong J, Lee S, Myungshin K, et al. Procalcitonin as a prognostic marker for sepsis based SEPSIS-3. J Clin Lab Anal. 2019;33(9):e22996. Citado en PubMed; PMID: 31420921.

  2. Rodríguez Y, Novelli L, Rojas M, et al. Autoinflammatory and autoimmune conditions at the crossroad of COVID-19. J of Autoimmunity [Internet]. 2020 Nov [citado 23/06/2020];114:102506. Disponible en: Disponible en: https://www.sciencedirect.com/science/article/pii/S0896841120301281

  3. Perrotta F, Corbi G, Mazzeo G, et al. COVID 19 and the elderly: insights into pathogenesis and clinical decision-making. Aging Clin Exp Res. 2020 Aug;32(8):1599-1608. Errata en: Aging Clin Exp Res. 2020 Sep;32(9):1909. Citado en PubMed; PMID: 32557332.

  4. Wang L, He W, Yu X, et al. Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up. J Infect. 2020 Jun;80(6):639-45. Citado en PubMed; PMID: 32240670.

  5. Kang S, Peng W, Zhu Y, et al. Recent progress in understanding 2019 novel coronavirus (SARS-CoV-2) associated with human respiratory disease: detection, mechanisms and treatment. Int J Antimicrob Agents. 2020 May;55(5):105950. Citado en PubMed; PMID: 32234465.

  6. Du RH, Liang LR, Yang CQ, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J. 2020 May 7;55(5):2000524. doi: 10.1183/13993003.00524-2020.

  7. Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020 Mar;63(3):364-74. Citado en PubMed; PMID: 32048163.

  8. Zeng F, Huang Y, Guo Y, et al. Association of inflammatory markers with the severity of COVID-19: A meta-analysis. Int J Infect Dis. 2020 Jul;96:467-74. Citado en PubMed; PMID: 32425643.

  9. Tan C, Huang Y, Shi F, et al. C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early. J Med Virol. 2020 Jul;92(7):856-62. Citado en PubMed; PMID: 32281668.

  10. Villar J, Zhang H, Slutsky A. Lung Repair and Regeneration in ARDS: Role of PECAM1 and Wnt Signaling. Chest. 2019 Mar;155(3):587-94. Citado en PubMed; PMID: 30392791.

  11. Zhang C, Wu Z, Li J, et al. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020 May;55(5):105954. Citado en PubMed; PMID: 32234467.

  12. Liu F, Lin L, MengDa X, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol. 2020 Jun;127:104370. Citado en PubMed; PMID: 32344321.

  13. Taylor R, Jones A, Kelly S, et al. A Review of the Value of Procalcitonin as a Marker of Infection. Cureus. 2017 Apr 10;9(4): e1148. Citado en PubMed; PMID: 28497010.

  14. Becher Y, Goldman L, Schacham N, et al. D-dimer and C-reactive Protein Blood Levels Over Time Used to Predict Pulmonary Embolism in Two COVID-19 Patients. Eur J Case Rep Intern Med. 2020;7(6):001725. Citado en PubMed; PMID: 32523928.

  15. McFadyen J, Stevens H, Peter K. The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications. Circ Res. 2020 Jul 31;127(4):571-87. Citado en PubMed; PMID: 32586214.

  16. Costanzo L, Palumbo F, Ardita G, et al. Coagulopathy, thromboembolic complications and the use of heparin in COVID-19 Pneumonia. J Vasc Surg Venous Lymphat Disord. 2020 Sep;8(5):711-6. Citado en PubMed; PMID: 32561465.

  17. Gouda M, Shaikh S, Bhandary Y. Inflammatory and Fibrinolytic System in Acute Respiratory Distress Syndrome. Lung. 2018 Oct;196(5):609-16. Citado en PubMed; PMID: 30121847.

  18. Thachil J. The protective rather than prothrombotic fibrinogen in COVID-19 and other inflammatory states. J Thromb Haemost. 2020 Aug;18(8):1849-52. Citado en PubMed; PMID: 32588535.

  19. Bi X, Su Z, Yan H, et al. Prediction of severe illness due to COVID-19 based on an analysis of initial Fibrinogen to Albumin Ratio and Platelet count. Platelets. 2020 Jul 3;31(5):674-9. Citado en PubMed; PMID: 32367765.

  20. Zhang Y, Cao W, Xiao M, et al. Clinical and coagulation characteristics in 7 patients with critical COVID-2019 pneumonia and acro-ischemia. Zhonghua Xue Ye Xue Za Zhi. 2020 Mar 28;41(0):e006. Citado en PubMed; PMID: 32220276.

  21. Siripanthong B, Nazarian S, Muser D, et al. Recognizing COVID-19-related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management. Heart Rhythm. 2020 Sep;17(9):1463-71. Citado en PubMed; PMID: 32387246.

  22. Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 in patients in Wuhan. J Allergy Clin Immunol. 2020 Jul;146(1):110-8. Citado en PubMed; PMID: 32294485.

  23. Medeiros Figueiredo A, Daponte-Codina A, Moreira Marculino D, et al. Factores asociados a la incidencia y la mortalidad por COVID-19 en las comunidades autónomas. Gac Sanit [Internet]. 2020 [citado 28/06/2020]. Disponible en: Disponible en: https://www.sciencedirect.com/science/article/pii/S0213911120301242?via%3Dihub

  24. Chen Q, Xu L, Dai Y, et al. Cardiovascular manifestations in severe and critical patients with COVID-19. Clin Cardiol. 2020 Jul;43(7):796-802. Citado en PubMed; PMID: 32562427.




2020     |     www.medigraphic.com